KR20150130466A - 췌장암을 치료하는 방법 - Google Patents

췌장암을 치료하는 방법 Download PDF

Info

Publication number
KR20150130466A
KR20150130466A KR1020157028505A KR20157028505A KR20150130466A KR 20150130466 A KR20150130466 A KR 20150130466A KR 1020157028505 A KR1020157028505 A KR 1020157028505A KR 20157028505 A KR20157028505 A KR 20157028505A KR 20150130466 A KR20150130466 A KR 20150130466A
Authority
KR
South Korea
Prior art keywords
seq
ser ser
sequence
antibody
notch3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157028505A
Other languages
English (en)
Korean (ko)
Inventor
티모시 찰스 호이
춘 장
앤 엠. 카포운
Original Assignee
온코메드 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코메드 파마슈티칼스, 인크. filed Critical 온코메드 파마슈티칼스, 인크.
Publication of KR20150130466A publication Critical patent/KR20150130466A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
KR1020157028505A 2013-03-15 2014-03-13 췌장암을 치료하는 방법 Withdrawn KR20150130466A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794788P 2013-03-15 2013-03-15
US61/794,788 2013-03-15
PCT/US2014/026094 WO2014151606A2 (en) 2013-03-15 2014-03-13 Methods of treating pancreatic cancer

Publications (1)

Publication Number Publication Date
KR20150130466A true KR20150130466A (ko) 2015-11-23

Family

ID=51581651

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157028505A Withdrawn KR20150130466A (ko) 2013-03-15 2014-03-13 췌장암을 치료하는 방법

Country Status (11)

Country Link
US (1) US20160030561A1 (enExample)
EP (1) EP2971146A4 (enExample)
JP (1) JP2016520289A (enExample)
KR (1) KR20150130466A (enExample)
CN (1) CN105051215A (enExample)
AU (1) AU2014233736A1 (enExample)
CA (1) CA2900969A1 (enExample)
HK (1) HK1211322A1 (enExample)
IL (1) IL240688A0 (enExample)
MX (1) MX2015011386A (enExample)
WO (1) WO2014151606A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
JP5618544B2 (ja) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
CN102316897B (zh) 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US9944700B2 (en) 2013-03-13 2018-04-17 Novartis Ag Notch2 binding molecules for treating respiratory diseases
CN109690314B (zh) * 2016-05-09 2022-08-02 法国国家卫生及研究医学协会 患有实体癌症的患者的分类方法
EP3595717A1 (en) * 2017-03-17 2020-01-22 Imclone, LLC Combination therapy for pancreatic cancer
EP3610042A1 (en) * 2017-04-14 2020-02-19 H. Hoffnabb-La Roche Ag Diagnostic and therapeutic methods for cancer
WO2019203255A1 (ja) * 2018-04-19 2019-10-24 公立大学法人横浜市立大学 再構成癌組織を用いた薬剤評価方法
WO2023225345A1 (en) * 2022-05-20 2023-11-23 Mayo Foundation For Medical Education And Research Treating chemoresistant cancers with notch3 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102390A1 (en) * 2002-11-21 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch3 expression
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
US7807630B2 (en) * 2007-09-14 2010-10-05 Vanderbilt University Targeting of Notch3 receptor function for cancer therapy
CN102316897B (zh) * 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
JP2012515547A (ja) * 2009-01-26 2012-07-12 アカデミス ズィーケンハイス レイデン ハー．オー．デー．エン． エルユーエムセー Ｎｏｔｃｈ３タンパク質発現および／またはｎｏｔｃｈ３のコード領域を調節するための手段および方法；ｃａｄａｓｉｌの処置におけるその組成物および使用
PH12012500574A1 (en) * 2009-09-30 2012-10-22 Genentech Inc Notch1-antagonist-resistant cancer(s) using notch3 antagonists

Also Published As

Publication number Publication date
US20160030561A1 (en) 2016-02-04
MX2015011386A (es) 2016-02-03
EP2971146A2 (en) 2016-01-20
CA2900969A1 (en) 2014-09-25
IL240688A0 (en) 2015-10-29
EP2971146A4 (en) 2016-11-09
WO2014151606A4 (en) 2015-01-29
CN105051215A (zh) 2015-11-11
WO2014151606A2 (en) 2014-09-25
JP2016520289A (ja) 2016-07-14
AU2014233736A1 (en) 2015-08-27
HK1211322A1 (en) 2016-05-20
WO2014151606A3 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
KR20150130466A (ko) 췌장암을 치료하는 방법
EP2911691B1 (en) Methods of treating neuroendocrine tumors using wnt pathway-binding agents
US20150132301A1 (en) Combination Therapy for Treatment of Cancer
US20170266276A1 (en) Combination Therapy For Treatment of Cancer
WO2013044215A9 (en) Vegf/dll4 binding agents and uses thereof
WO2014012007A2 (en) Rspo3 binding agents and uses thereof
US20160243223A1 (en) Methods for treating cancers comprising k-ras mutations
US9480744B2 (en) Methods for treating melanoma
US20170247465A1 (en) Combination therapy for treatment of cancer
US20170022289A1 (en) Methods for treating cancer with notch1 antiboides
US20150232570A1 (en) Methods of Treating Hematological Malignancies with Notch1 Antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151012

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid